Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.

Ajay Nehra1

  • 1Department of Urology, Mayo Clinic, Rochester, MN 55905, USA. nehra.ajay@mayo.edu

BJU International
|July 27, 2005
PubMed
Summary

This review discusses managing sexual function in benign prostatic hyperplasia (BPH) patients, exploring neurotransmitter roles and therapeutic targets like the nitric oxide/cGMP pathway for bladder outlet obstruction (BOO). It also covers robotic surgery advancements and academic creativity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostate and pancreas involvement are linked in IgG4-related disease.

Seminars in arthritis and rheumatism·2020
Same author

The Role of Oxygen Tension in Penile Erection and Its Relationship to Erectile Dysfunction.

TheScientificWorldJournal·2018
Same author

Erectile Dysfunction: AUA Guideline.

The Journal of urology·2018
Same author

Prostate cancer in renal transplant recipients.

International braz j urol : official journal of the Brazilian Society of Urology·2017
Same author

Procalcitonin is a strong predictor of urine culture results in patients with obstructing ureteral stones: A prospective, pilot study.

Urology annals·2016
Same author

Peyronie's Disease: AUA Guideline.

The Journal of urology·2015

Area of Science:

  • Urology
  • Andrology
  • Academic Medicine

Background:

  • Benign prostatic hyperplasia (BPH) frequently co-exists with lower urinary tract symptoms (LUTS) and sexual dysfunction.
  • Altered neurotransmitter regulation, particularly noradrenaline, is implicated in the pathophysiology of LUTS and sexual dysfunction in BPH.
  • Current therapeutic strategies for BPH often require careful consideration of their impact on sexual function.

Purpose of the Study:

  • To review the selection of therapy for maintaining sexual function in patients with BPH.
  • To explore the role of neurotransmitters in LUTS and sexual dysfunction associated with BPH.
  • To discuss the application of robotic surgery in renal and adrenal disorders and potential therapeutic targets for BPH-associated bladder outlet obstruction (BOO).

Main Methods:

Related Experiment Videos

  • Literature review of therapeutic options for BPH and sexual dysfunction.
  • Analysis of the role of neurotransmitters, specifically noradrenaline, in the BPH syndrome.
  • Evaluation of current and future applications of robotic surgery for urological and adrenal conditions.
  • Exploration of the nitric oxide/cGMP pathway as a therapeutic target for BOO.

Main Results:

  • Therapy selection for sexual function maintenance in BPH patients is outlined.
  • The link between noradrenergic dysregulation and LUTS/sexual dysfunction is explained.
  • Robotic surgery's status and future in renal/adrenal disorders are presented.
  • The nitric oxide/cGMP pathway shows potential for treating BOO in BPH.

Conclusions:

  • Optimizing sexual function requires careful therapeutic selection in BPH management.
  • Understanding neurotransmitter roles offers insights into BPH-related syndromes.
  • Robotic surgery is advancing in urological and adrenal applications.
  • Targeting the nitric oxide/cGMP pathway presents a promising avenue for BOO treatment in BPH.